You are here


Correction: An article in the September issue of P&T, page 502, incorrectly stated that the FDA considers Vascepa to be a new chemical entity (NCE). In fact, the FDA has not yet decided whether to grant the drug new chemical entity marketing exclusivity. P&T regrets the error.